Medicare Enrolled
Dr. Paul Kenworthy, MD
Urology Physician · Huntsville, TX
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kenworthy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kenworthy?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kenworthy
Dr. Paul Kenworthy is an urology physician in Huntsville, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Kenworthy performed 5,522 Medicare services across 2,832 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kenworthy received a total of $16,514 from 34 pharmaceutical and/or device companies across 148 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kenworthy is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 21% volume in TX
$16,514 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,522
Medicare services
Top 21% in TX for urology physician
2,832
Unique beneficiaries
$48
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~276 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Infectious disease DNA/RNA test A laboratory test that uses a specific technique to detect the genetic material of an organism. This method amplifies the target DNA or RNA to identify the presence of the organism. |
1,132 | $34 | $71 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
635 | $2 | $14 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
496 | $83 | $250 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
490 | $7 | $20 |
| Yeast/candida DNA test A laboratory test that uses an amplified probe technique to detect the presence of Candida species, a type of yeast, in a patient sample. |
436 | $34 | $71 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
341 | $58 | $176 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
284 | $8 | $12 |
| Urinalysis with microscopic exam A urine test performed manually that includes examining the sample under a microscope to check for abnormalities. |
254 | $3 | $18 |
| Nucleic acid test for multiple organisms A laboratory test that uses amplified probe techniques to detect the genetic material of multiple organisms in a sample. |
154 | $69 | $140 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
147 | $166 | $479 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 109 | $132 | $695 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
95 | $108 | $324 |
| Staphylococcus aureus DNA test A laboratory test that uses DNA amplification to detect the presence of Staphylococcus aureus bacteria in a sample. |
88 | $34 | $72 |
| MRSA nucleic acid detection test A laboratory test that uses amplified probe techniques to detect the genetic material of methicillin-resistant Staphylococcus aureus (MRSA) bacteria. |
88 | $34 | $72 |
| Group B Strep DNA test A laboratory test that uses DNA amplification to detect the presence of Group B Streptococcus bacteria. |
88 | $34 | $71 |
| Strep A nucleic acid amplification test A laboratory test that uses nucleic acid amplification to detect the presence of Group A Streptococcus bacteria. This method identifies the genetic material of the bacteria to determine if an infection is present. |
86 | $34 | $71 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
62 | $71 | $216 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
57 | $60 | $138 |
| VRE nucleic acid detection test A laboratory test that uses amplified probe techniques to detect vancomycin-resistant Enterococcus (VRE) DNA in a patient sample. |
52 | $34 | $71 |
| Simple change of bladder tube | 51 | $67 | $190 |
| Transrectal ultrasound of the pelvis An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures. |
49 | $100 | $399 |
| Additional urethral implant in prostate Placement of an additional implant into the urethra within the prostate gland using an endoscope. |
42 | $658 | $1,784 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
41 | $0 | $15 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
37 | $26 | $65 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
37 | $37 | $110 |
| Bladder irrigation and/or instillation This procedure involves flushing the bladder with fluid to clear it or introducing medication directly into the bladder. |
32 | $54 | $150 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
29 | $99 | $261 |
| Simple insertion of temporary bladder tube A procedure to place a temporary tube into the bladder. This allows for the drainage of urine from the bladder. |
27 | $43 | $122 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
27 | $15 | $45 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
21 | $91 | $198 |
| Urethral implant insertion in prostate A single implant is placed into the urethra within the prostate gland using an endoscope. |
12 | $967 | $2,595 |
| Prostate gland biopsy A procedure to remove small samples of tissue from the prostate gland for laboratory examination. |
12 | $148 | $478 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
11 | $110 | $383 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$16,514
Total received (2018-2024)
Avg $2,359/year across 7 years
Top 14% in TX for urology physician
34
Companies
148
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$11,332 (68.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,182 (31.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$429
2023
$2,062
2022
$429
2021
$3,629
2020
$109
2019
$7,870
2018
$1,986
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
NeoTract Inc.
$9,069
Teleflex LLC
$2,790
PROCEPT BioRobotics Corporation
$1,470
Valencia Technologies Corporation
$1,110
Astellas Pharma US Inc
$489
ABBVIE INC.
$118
PALETTE LIFE SCIENCES, INC.
$117
Axonics, Inc.
$115
UROGEN PHARMA, INC.
$110
Janssen Biotech, Inc.
$102
Laborie Medical Technologies Corp.
$102
C. R. Bard, Inc. & Subsidiaries
$92
Antares Pharma, Inc.
$90
EDAP TECHNOMED INC
$69
Rochester Medical Corporation
$65
PFIZER INC.
$60
Aytu BioScience, Inc
$52
Merck Sharp & Dohme Corporation
$49
Avadel Specialty Pharmaceuticals, LLC
$45
TherapeuticsMD, Inc.
$44
Allergan Inc.
$39
Myovant Sciences Inc.
$37
PROGENICS PHARMACEUTICALS, INC.
$35
C. R. BARD, INC. & SUBSIDIARIES
$33
AbbVie Inc.
$28
Alnylam Pharmaceuticals Inc.
$28
Agiliti Surgical, Inc.
$24
MEDIVATION FIELD SOLUTIONS LLC
$23
BOSTON SCIENTIFIC CORPORATION
$22
Retrophin, Inc.
$21
Cook Medical LLC
$18
AbbVie, Inc.
$17
UROVANT SCIENCES INC
$16
Myriad Genetic Laboratories, Inc.
$13
Top 3 companies account for 80.7% of total payments
Associated products mentioned in payments ›
(815) Thiola · AQUABEAM ROBOTIC SYSTEM · AQUABEAM SYSTEM · AVYCAZ · Axonics · Axonics r-SNM System · BOTOX THERAPEUTIC · BRACANALYSIS CDX · Bard Urinary Drainage Bag · ERLEADA · Erleada · GEMTESA · GENERAL BPH · IMVEXXY · JELMYTO · LUPRON DEPOT · LYNPARZA · Lupron Depot · MYRBETRIQ · Myrbetriq · NCIRCLE · NOCDURNA · Natesto · Noctiva · ORGOVYX · OXLUMO · PYLARIFY · TOVIAZ · UROLIFT · UROLIFT SYSTEM · UroLift · UroLift System · XTANDI · XYOSTED · Xtandi · ZYTIGA · eCoin Device Kit
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (69%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in urology physician and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $299 per 100 Medicare services performed
Geographic Context
Urology physicians within 10 mi
4
Per 100K population
5.1
County median income
$49,862
Nearest hospital
HUNTSVILLE MEMORIAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kenworthy is a clinical cardiology specialist, with above-average Medicare volume (top 21% in TX), with speaking/promotional industry engagement in the top 14% of TX peers, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kenworthy experienced with infectious disease dna/rna test?
Based on Medicare claims data, Dr. Kenworthy performed 1,132 infectious disease dna/rna test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kenworthy receive payments from pharmaceutical companies?
Yes. Dr. Kenworthy received a total of $16,514 from 34 companies across 148 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kenworthy's costs compare to other urology physicians in Huntsville?
Dr. Kenworthy's average Medicare payment per service is $48. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kenworthy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Huntsville
Browse urology physicians in Huntsville ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in TX
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in TX
Which TX urology physicians receive the most from drug and device companies.
By company
NeoTract Inc. Payments to Doctors
See all physicians who received payments from NeoTract Inc.
By company
Teleflex LLC Payments to Doctors
See all physicians who received payments from Teleflex LLC.
By company
PROCEPT BioRobotics Corporation Payments to Doctors
See all physicians who received payments from PROCEPT BioRobotics Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology